ALK and adenocarcinoma: In the case of adenocarcinoma, in particular, driver mutations and the corresponding drugs already exists and thus, it reacts well to targeted therapy, which includes, but is not limited to EGFR, ALK, and ROS1, resulting in good outcomes.